Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)

Milger, Katrin; Korn, Stephanie; Feder, Claudia; Fuge, Jan; Mühle, A.; Schütte, Wolfgang; Skowasch, Dirk; Timmermann, Hartmut; Suhling, Hendrik

doi:10.1055/a-2014-4350

Cited by 12 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…All pulmonary function tests (PFT) were performed under continued stable inhaled therapy. Responder status was assessed using Biologics Asthma Response Score (BARS) recently published by Milger et al 25 Patients classified “responder” or “partial responder” were grouped in the “responder group”.…”

Section: Methodsmentioning

confidence: 99%

“…The main advantage of our study is the classification of our treated patients in responder and non-responder according to the novel BARS Score that as universally applicable to classify mAb-therapy response. 25 Limitations: The generalizability of our study is limited by its monocentric and retrospective design as well as the relatively small sample size. Further, using HADS in combination with PHQ-2 and GAD-2 scores to estimate the followup to classify patients with probable MDD and/or GAD does not allow diagnosis of mental disorders.…”

mentioning

confidence: 98%

See 2 more Smart Citations

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

Plank¹,

Hinze²,

Campbell³

et al. 2023

JAA

Self Cite

View full text Add to dashboard Cite

Purpose Asthma is associated with a high prevalence of psychopathological disorders, especially depressive disorders or anxiety. In patients with uncontrolled severe asthma, monoclonal antibody (mAb)-therapy positively influenced control of mental disorders. Therefore, we evaluated the impact of antibody therapy on the burden of these mental diseases depending on responder status. Patients and Methods Data were collected retrospectively in patients with uncontrolled severe asthma (n = 82) prior to mAb-therapy (“baseline”) (omalizumab, dupilumab, benralizumab or mepolizumab). Symptoms of Major Depressive Disorder (MDD) or General Anxiety Disorder (GAD) were detected at baseline using the Hospital Anxiety and Depression Scale (HADS), as well as general sociodemographic data and lung function parameters. At 6-month (±3 month) follow-up, the burden of psychopathological symptoms under mAb-therapy was assessed using the Patient Health Questionnaire-2 (PHQ-2) and Generalized Anxiety Disorder Scale-2 (GAD-2). Response status was classified using the Biologics Asthma Response Score (BARS), assessing exacerbations, oral corticosteroid usage and asthma control test (ACT) score. Predictors for non-response to mAb-therapy were identified using linear regression analysis. Results Patients with severe asthma suffered from symptoms of MDD/GAD more often compared to the general population, with a higher prevalence among mAb therapy non-responders. mAb-responders exhibited a declining burden of MDD, better quality of life (QoL), less exacerbations, better lung function and better disease control compared to non-responders. A history of symptoms of depression was identified as a predictor for non-response to mAb-therapy. Conclusion Asthma symptoms and psychological problems are linked and more prevalent in our cohort of severe asthma patients than in the general population. Patients with signs of MDD/GAD before mAb-therapy show less mAb therapy response suggesting a negative impact of prior psychological problems on treatment response. In some patients, the score on MDD/GAD was caused by severe asthma – here symptoms decreased after effective treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 98%

See 1 more Smart Citation

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

Plank¹,

Hinze²,

Campbell³

et al. 2023

JAA

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, a German consensus group published the BAR-Score, a scoring system for biologic therapy response in severe asthma allowing for easier and more objective treatment comparisons. [22] Calculated through assessment of ACT, annualized exacerbation rate and reduction of steroid dose, BARS allows for categorization of biologic recipients into "good response", "intermediate responders" and "insu cient response". [22] Using BARS, we found that around half of all patients attained a good response, with another quarter showing intermediate response, irrespective of group.…”

Section: Discussionmentioning

confidence: 99%

“…A higher score corresponds to a better therapy response, with the overall response being assessed using the average of all three categories, allowing for categorization of therapy response into one of three categories ("good response", "intermediate responders" and "insu cient response"). [22]…”

Section: Data Collectionmentioning

confidence: 99%

Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy

Kayser,

Suhling,

Fuge

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background Monoclonal antibodies (biologics) drastically changed severe asthma therapy. Mepolizumab (anti-interleukin (IL) 5), benralizumab (anti-IL5 receptor alpha), and dupilumab (anti-IL4/13) are the most used biologics in this context. While all biologics are efficient individually, the choice of biologic is complicated by insufficient data on their comparative long-term treatment efficacy. Here, we compare the real-life efficacy of these biologics in asthma therapy over 12 months. Methods 280 severe asthma patients treated with mepolizumab (129/280, 46%), benralizumab (83/280, 30%) or dupilumab (68/280, 24%) for one year were analyzed retrospectively. Data were collected at baseline and after 6 and 12 months of therapy. Endpoints were changes pulmonary function (PF), exacerbation rate, oral corticosteroid (OCS) use and dose, asthma control test (ACT) score and fractional exhaled nitric oxide (FeNO) levels as well as responder status measured by the recently published “Biologic Asthma Response Score” (BARS). Results All biologics led to significant improvements in PF, ACT and OCS dose. Only Mepolizumab and Benralizumab significantly decreased the exacerbation rate, while only Mepolizumab and Dupilumab significantly decreased FeNO. Responder rates measured by BARS were high across all groups: roughly half of all patients achieved full response and most of the remainder achieved at least partial responder status. Overall, outcomes were similar between groups after both 6 and 12 months. Conclusions All biologics showed great efficacy in individual parameters and high responder rates measured by BARS without a clinically relevant advantage for any antibody. Response was usually achieved after 6 months and retained at 12 months, emphasizing the utility of early response assessment.

show abstract

Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma

Kayser

Jülicher

Welte

et al. 2024

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Kriterien zur Evaluation des Ansprechens auf Biologika bei schwerem Asthma – der Biologics Asthma Response Score (BARS)

Cited by 12 publications

References 39 publications

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

Relationship Between the Response to Antibody Therapy and Symptoms of Depression and Anxiety Disorders in Patients with Severe Asthma

Long-term multicenter comparison shows equivalent efficacy of monoclonal antibodies in severe asthma therapy

Retrospective assessment and Biologic Asthma Response Score reveal roadmap for switching biologics in severe asthma

Contact Info

Product

Resources

About